CRISPR Therapeutics AG CRSP
40.15 USD 0.00 (+0.00%)
Regular-session close
40.96 +0.81 +2.02%
Pre-market · Nov 18, 9:03 AM ET
39.80 Day range 41.17
39.80 52-week range 63.45
- YTD
- -23.44%
- 1 year
- -27.42%
News
zacks.com CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know Recently, Zacks.com users have been paying close attention to CRISPR Therapeutics (CRSP). This makes it worthwhile to examine what the stock has in store.
marketbeat.com CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build CRISPR Therapeutics NASDAQ: CRSP is preparing to advance several experimental treatments toward late-stage trials, with executives pointing to upcoming data from its cardiovascular and cell therapy…
benzinga.com CRISPR Therapeutics Highlights Substantial Lipid Reductions with Investigational Gene Editing Therapy CRISPR Therapeutics reported Phase 1b data for CTX310, showing a 63% triglyceride drop and solid safety in severe hypertriglyceridemia.benzinga.com CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases -Data presented in a late-breaking oral presentation at AHA--A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG)…
benzinga.com Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all…
benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
benzinga.com Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70 Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.
benzinga.com CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses…
benzinga.com CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad CRISPR Therapeutics (NASDAQ:CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the…
